Financial Daily from THE HINDU group of publications
Saturday, Jan 22, 2005

News
Features
Stocks
Port Info
Archives
Google

Group Sites

Home Page - Pharmaceuticals
Corporate - Management


Top-level rejig at Ranbaxy

Our Bureau

New Delhi , Jan. 21

PHARMA major Ranbaxy Laboratories Ltd on Friday announced a top-level restructuring, including internal reshuffles and appointments from outside the organisation.

Pointing out that the appointments are in line with the company's targeted revenues of $2 billion by 2007, a company statement informed that the top management team now consists of 27 vice-presidents and three executive directors.

"These new positions have been created to provide leadership and focus in the critical areas of clinical research, global quality, sales and marketing, legal and secretarial, global corporate communications and public affairs, and other key disciplines requiring significant attention and top management expertise," the company said.

Mr Ramesh Adige, Vice-President for Corporate Affairs, has been elevated to the company's board while Mr R. Sundar Rajan, from Wipro, has been taken in as Vice-President (Legal).

Mr Sundar Rajan was the Corporate Vice-President Legal & Group General Counsel in Wipro and "brings with him rich and varied experience in the legal and secretarial functions and a significant knowledge base in mergers and acquisitions," the CEO and Managing Director of Ranbaxy, Dr Brian Tempest, said.

Additionally, seven senior executives of the company have been promoted as vice-presidents.

Dr R. Gowrishankar is now the Vice-President (Clinical Research); Mr Jim Meehan, who has been instrumental in setting up an extensive distribution system for Ranbaxy's expanding product portfolio in the US, is now the Vice-President, Sales (Marketing & Distribution).

"This strengthens the company's generic sales and marketing initiative in the highly competitive North American market," said the company statement.

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page


Stories in this Section
Investments in Reliance Infocomm — `No violation of corporate governance norms'


Reliance Ind net leaps 52 pc in third quarter on higher margins
Top-level rejig at Ranbaxy
AES Corp, CLP Power are back; bid for UP project
Wipro clocks 56 pc rise in Q3 net at Rs 427 cr
Brazil lifts dumping duty on Indian jute bags
The nation that talks a lot
Contributions to The Hindu Relief Fund


The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | The Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright © 2005, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line